Health Canada Issues Notice of Compliance for Bausch Health's BRYHALI

 
 

 Bausch Health, Canada which is part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), ("Bausch Health" or the "Company") today announced that Health Canada has approved the use of BRYHALI (Halobetasol Propionate Lotion 0.01% ww), a high to super-high potency topical corticosteroid indicated for Corticosteroid-Responsive Dermatoses and the topical treatment of plaque psoriasis.i Some of the most "commonly-encountered skin disorders under the Corticosteroid-Responsive Dermatoses umbrella include seborrheic dermatitis and eczematous dermatoses such as atopic dermatitis and contact dermatitis." ii

 
 

  Bausch Health logo (CNW Group/Bausch Health) 

 
 

BRYHALI lotion is formulated with PRISMATREX™  technology, a novel polymeric emulsification system, which provides a stable condition where emulsion droplets retain their distribution across time and temperature. iii BRYHALI is applied once daily and can be used for up to eight weeks.

 

"With Health Canada's approval of BRYHALI, patients suffering from corticosteroid-responsive dermatoses and will soon have an innovative topical treatment option with the active ingredient halobetasol propionate, a corticosteroid designed to help reduce inflammation," said Ginette Gagné, Interim President and General Manager, Bausch Health , Canada . "BRYHALI is a welcome addition to our dermatology portfolio, which is comprised of the largest number of innovative dermatology products in Canada , and we remain committed to bringing forward new medicines to help improve the lives of Canadians."

 

"Topical corticosteroids are commonly used for many corticosteroid-responsive dermatoses – they are known to offer relief from itching and inflammation," said Dr. Shear, dermatologist, professor emeritus, University of Toronto . "BRYHALI lotion is a welcome new addition, offering a lotion that is formulated with the PRISMATREX™  technology system."

 

BRYHALI will be available in Canada in the coming months.

 

BRYHALI is manufactured at the Company's Laval, Quebec manufacturing facility for both Canadian and U.S. patients.

 

  About Bausch Health Companies Inc.
Bausch Health Companies Inc. (NYSE/TSX: BHC ) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

In Canada, the Company's prescription product portfolio is focused on eye health, dermatology, and cardio-metabolic conditions. More information can be found on the Company's website at   bauschhealth.ca   .

 
 
         
 

  References  

 
 
 
 

  i.  

 
 

  PM BRYHALI, April 13, 2021  

 
 

  ii.  

 
 

  Kircik LH, Del Rosso JQ. The treatment of inflammatory facial dermatoses with topical corticosteroids: focus on clocortolone pivalate 0.1% cream. J Drugs Dermatol. 2012 Oct;11(10):1194-8. PMID: 23134984.  

 
 

  iii.  

 
 

  Data in Health Canada NDS submission  

 
 
 
 
 

SOURCE Bausch Health

 

 

 

 Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/May2021/05/c3468.html  

 
 

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
Bausch Health Companies Inc.

Bausch Health Companies Inc.

Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.

illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×